combine@alvar.ug

Human immunodeficiency virus care cascade among sub-populations in Rakai, Uganda: an observational study

Human immunodeficiency virus care cascade among sub-populations in Rakai, Uganda: an observational study

Show simple record

dc.contributor.author Billioux, Veena G.
dc.contributor.author Chang, Larry W.
dc.contributor.author Reynolds, Steven J.
dc.contributor.author Nakigozi, Gertrude
dc.contributor.author Ssekasanvu, Joseph
dc.contributor.author Grabowski, Mary K.
dc.contributor.author Ssekubugu, Robert
dc.contributor.author Nalugoda, Fred
dc.contributor.author Kigozi, Godfrey
dc.contributor.author Kagaayi, Joseph
dc.contributor.author Serwadda, David
dc.contributor.author Gray, Ronald H.
dc.contributor.author Wawer, Maria J.
dc.date.accessioned 2021-01-01T21:58:22Z
dc.date.available 2021-01-01T21:58:22Z
dc.date.issued 2017
dc.identifier.uri http://combine.alvar.ug/handle/1/48281
dc.description.abstract Introduction: To assess progress towards the UNAIDS 90-90-90 initiative targets, we examined the HIV care cascade in the population-based Rakai Community Cohort Study (RCCS) in rural Uganda and examined differences between sub-groups. Methods: Self-reports and clinical records were used to assess the proportion achieving each stage in the cascade. Statistical inference based on a chi(2) test for categorical variables and modified Poisson regression were used to estimate prevalence risk ratios (PRRs) and 95% confidence intervals (CI) for enrolment into care and initiating antiretroviral therapy (ART). Results: From September 2013 through December 2015, 3,666 HIV-positive participants were identified in the RCCS. As of December 2015, 98% had received HIV Counseling and Testing (HCT), 74% were enrolled in HIV care, and 63% had initiated ART of whom 92% were virally suppressed after 12 months on ART. Engagement in care was lower among men than women (enrolment in care: adjPRR 0.84, 95% CI 0.77-0.91; ART initiation: adjPRR 0.75, 95% CI 0.69-0.82), persons aged 15-24 compared to those aged 30-39 (enrolment: adjPRR 0.72, 95% CI 0.63-0.82; ART: adjPRR 0.69, 95% CI 0.60-0.80), unmarried persons (enrolment: adjPRR 0.84, 95% CI 0.71-0.99; ART adjPRR 0.80, 95% CI 0.66-0.95), and new in-migrants (enrolment: adjPRR 0.75, 95% CI 0.67-0.83; ART: adjPRR 0.76, 95% CI 0.67-0.85). This cohort achieved 98-65-92 towards the UNAIDS "90-90-90" targets with an estimated 58% of the entire HIV-positive RCCS population virally suppressed. Conclusions: This cohort achieved over 90% in both HCT and viral suppression among ART users, but only 65% in initiating ART, likely due to both an ART eligibility criterion of <500 CD4 cells/mL and suboptimal entry into care among men, younger individuals, and in-migrants. Interventions are needed to promote enrolment in HIV care, particular for hard-to-reach subpopulations.
dc.description.sponsorship National Institute of Allergy and Infectious DiseasesUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID) [RO1AI114438, RO1AI110324, UO1AI10031]
dc.description.sponsorship Division of Intramural ResearchUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA
dc.description.sponsorship National Institute of Mental HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [RO1MH107275]
dc.description.sponsorship National Institute of Child Health and Human DevelopmentUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [RO1HD070769]
dc.description.sponsorship Bill & Melinda Gates FoundationBill & Melinda Gates Foundation [22006.03]
dc.description.sponsorship World BankThe World Bank India [7166975]
dc.description.sponsorship Centers for Disease control and Protection [USGPS000971]
dc.description.sponsorship NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID) [ZIAAI001040, P30AI094189, P30AI094189, P30AI094189, P30AI094189, P30AI094189, P30AI094189, P30AI094189, P30AI094189, ZIAAI001040, P30AI094189, K01AI125086, ZIAAI001040, P30AI094189, P30AI094189, P30AI094189, P30AI094189, P30AI094189, ZIAAI001040, ZIAAI001040, P30AI094189, P30AI094189, P30AI094189, P30AI094189, P30AI094189, P30AI094189, P30AI094189, P30AI094189, P30AI094189, R01AI110324, P30AI094189, P30AI094189, P30AI094189, P30AI094189, ZIAAI001040, P30AI094189, P30AI094189, P30AI094189, P30AI094189, P30AI094189, P30AI094189, P30AI094189, P30AI094189, P30AI094189, P30AI094189, P30AI094189, P30AI094189, P30AI094189, P30AI094189, P30AI094189, P30AI094189, P30AI094189, P30AI094189, ZIAAI001040, P30AI094189, P30AI094189, P30AI094189, K01AI125086, P30AI094189, ZIAAI001040, P30AI094189, R01AI114438, P30AI094189, P30AI094189, P30AI094189, ZIAAI001040, ZIAAI001040, P30AI094189, P30AI094189, P30AI094189, P30AI094189, P30AI094189, ZIAAI001040, P30AI094189, P30AI094189, P30AI094189, P30AI094189, P30AI094189, P30AI094189, P30AI094189, P30AI094189, K01AI125086, P30AI094189, P30AI094189, P30AI094189, P30AI094189, P30AI094189, K01AI125086, P30AI094189, P30AI094189, P30AI094189, P30AI094189, P30AI094189] Funding Source: NIH RePORTER
dc.description.sponsorship NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R01MH107275, R01MH107275, R01MH107275, R01MH107275, R01MH107275] Funding Source: NIH RePORTER
dc.language English
dc.publisher JOHN WILEY & SONS LTD
dc.relation.ispartof Journal of the International AIDS Society
dc.subject Hiv
dc.subject Antiretroviral
dc.subject Hiv Care Cascade
dc.subject Rakai
dc.subject Uganda
dc.title Human immunodeficiency virus care cascade among sub-populations in Rakai, Uganda: an observational study
dc.type Article
dc.identifier.isi 000402641500001
dc.identifier.doi 10.7448/IAS.20.1.21590
dc.identifier.pmid 285171
dc.publisher.city CHICHESTER
dc.publisher.address THE ATRIUM, SOUTHERN GATE, CHICHESTER PO19 8SQ, W SUSSEX, ENGLAND
dc.identifier.eissn 1758-2652
dc.identifier.volume 20
dc.subject.wc Immunology
dc.subject.wc Infectious Diseases
dc.subject.sc Immunology
dc.subject.sc Infectious Diseases
dc.description.oa DOAJ Gold
dc.description.oa Green Published
dc.description.pages 9
dc.contributor.group Rakai Hlth Sci Program
dc.subject.kwp Hiv-Infected Patients
dc.subject.kwp Antiretroviral Therapy
dc.subject.kwp Early Retention
dc.subject.kwp Viral Load
dc.subject.kwp Transmission
dc.subject.kwp Plasma
dc.subject.kwp Seroconversion
dc.subject.kwp Probability
dc.subject.kwp Engagement
dc.subject.kwp Prevention
dc.identifier.articleno 21590
dc.description.affiliation Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, 627 North Washington St, Baltimore, MD 21205 USA
dc.description.affiliation Rakai Hlth Sci Program, Dept Rakai Community Cohort Study, Kalisizo, Uganda
dc.description.affiliation Johns Hopkins Sch Med, Dept Med, Div Infect Dis, Baltimore, MD USA
dc.description.affiliation NIAID, Immunoregulat Lab, Div Intramural Res, NIH, Bldg 10, Bethesda, MD 20892 USA
dc.description.affiliation Makerere Univ, Dept Dis Control & Environm Hlth, Sch Publ Hlth, Kampala, Uganda
dc.description.email vgoud1@jhu.edu
dc.description.corr Billioux, VG (corresponding author), Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, 627 North Washington St, Baltimore, MD 21205 USA.
dc.description.orcid Reynolds, Steven/0000-0002-5403-2759


This record appears in the collections of the following institution(s)

Show simple record

Search Entire Database


Browse

My Account